Your browser doesn't support javascript.
loading
SARS-CoV-2 antibody responses in solid organ transplant recipients.
Zervou, Fainareti N; Ali, Nicole M; Neumann, Henry J; Madan, Rebecca Pellett; Mehta, Sapna A.
Afiliación
  • Zervou FN; Department of Medicine, Grossman School of Medicine, New York University, New York City, New York, USA.
  • Ali NM; Department of Medicine, Grossman School of Medicine, New York University, New York City, New York, USA.
  • Neumann HJ; Langone Transplant Institute, New York University, New York City, New York, USA.
  • Madan RP; Department of Medicine, Grossman School of Medicine, New York University, New York City, New York, USA.
  • Mehta SA; Langone Transplant Institute, New York University, New York City, New York, USA.
Transpl Infect Dis ; 23(5): e13728, 2021 Oct.
Article en En | MEDLINE | ID: mdl-34505324
Antibody responses among immunocompromised solid organ transplant recipients (SOT) infected with Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) may be diminished compared to the general population and have not been fully characterized. We conducted a cohort study at our transplant center to investigate the rate of seroconversion for SARS-CoV-2 IgG antibodies among SOT recipients who were diagnosed with Coronavirus disease 2019 (COVID-19) and underwent serum SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) testing. The 61 patients who were included in the final analysis underwent initial SARS-CoV-2 IgG testing at a median of 62 days (Interquartile range 55.0-75.0) from symptom onset. Note that, 51 of 61 patients (83.6%) had positive SARS-CoV-2 IgG results, whereas 10 (16.4%) had negative IgG results. Six (60%) out of 10 seronegative patients underwent serial IgG testing and remained seronegative up to 17 weeks post-diagnosis. Use of belatacept in maintenance immunosuppression was significantly associated with negative IgG antibodies to SARS-CoV-2 both in univariate and multivariate analyses (Odds ratio 0.04, p = .01). In conclusion, the majority of organ transplant recipients with COVID-19 in our study developed SARS-CoV-2 antibodies. Further longitudinal studies of the durability and immunologic role of these IgG responses and the factors associated with lack of seroconversion are needed.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Órganos / COVID-19 Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Transpl Infect Dis Asunto de la revista: TRANSPLANTE Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Dinamarca
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Órganos / COVID-19 Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Transpl Infect Dis Asunto de la revista: TRANSPLANTE Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Dinamarca